Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing.

Agundez-Moreno A, Presas-Rodríguez S, González-García A M, Teniente-Serra A, Arcos-Ribas B, Martínez-Caceres E M, Querol L, Martín-Aguilar L, Vidal-Jordana Á, Meca Lallana JE, et al.